Cargando…

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

BACKGROUND: Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib demonstrated central nervous system activity in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gen, Soei, Tanaka, Ichidai, Morise, Masahiro, Koyama, Junji, Kodama, Yuta, Matsui, Akira, Miyazawa, Ayako, Hase, Tetsunari, Hibino, Yoshitaka, Yokoyama, Toshihiko, Kimura, Tomoki, Yoshida, Norio, Sato, Mitsuo, Hashimoto, Naozumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195197/ https://www.ncbi.nlm.nih.gov/pubmed/35698083 http://dx.doi.org/10.1186/s12885-022-09741-8

Ejemplares similares

Oxytocin receptor is a promising therapeutic target of malignant mesothelioma
por: Kodama, Yuta, et al.
Publicado: (2021)

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer
por: Matsuzawa, Reiko, et al.
Publicado: (2021)

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
por: Sato, Mitsuo, et al.
Publicado: (2018)

Is area under the curve the best parameter for carboplatin induced emetic risk stratification?
por: Ozone, Sachiko, et al.
Publicado: (2021)

Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer
por: Shimizu, Takahiro, et al.
Publicado: (2020)

eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer
por: Tanaka, Ichidai, et al.
Publicado: (2018)

Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
por: Tanaka, Ichidai, et al.
Publicado: (2023)

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight
por: Fujiwara, Yutaka, et al.
Publicado: (2023)

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
por: Tanaka, Ichidai, et al.
Publicado: (2021)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence
por: Tanaka, Ichidai, et al.
Publicado: (2021)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016)

Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells
por: Yamashita, Ryo, et al.
Publicado: (2015)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
por: Hara, Reina, et al.
Publicado: (2021)

Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer
por: Kakumu, Tomohiko, et al.
Publicado: (2017)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018)

Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report
por: Fukuda, Yuko, et al.
Publicado: (2022)

The relationship between pedal force application technique and the ability to perform supramaximal pedaling cadences
por: Yamaguchi, Yuta, et al.
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
por: Kobayashi, Tomoko, et al.
Publicado: (2018)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
por: Makimoto, Go, et al.
Publicado: (2020)

Distant metastasis in patients with myxofibrosarcoma
por: Tsuchie, Hiroyuki, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903
por: Ito, K., et al.
Publicado: (2021)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
por: Chihara, Yusuke, et al.
Publicado: (2022)

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
por: Kobayashi, Tomoko, et al.
Publicado: (2020)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

(11)C-methionine- and (18)F-FDG-PET double-negative metastatic brain tumor from lung adenocarcinoma with paradoxical high (18)F-FDG uptake: A case report
por: Tanahashi, Kuniaki, et al.
Publicado: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

Silencing of GRHL2 induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth
por: Kawabe, Nozomi, et al.
Publicado: (2023)

Finding chinks in the osimertinib resistance armor
por: Leal, Jose Luis, et al.
Publicado: (2020)

Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty
por: Sato, Mitsuo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_19ntkd3gn2olu3ls9p931drnb8